ResMed Inc. (RMD) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 24/100
- 10Y CAGR
- 11.9%
- Median YoY
- 12%
- YoY volatility
- σ 5.0pp· very smooth
- Quarters ≥ 20%
- 3 of 40
- Negative quarters
- 1
- Valuation vs own 10Y history
- P/S 5.9x · 10Y median 7.1x · 24th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 3 of 40 → 3 of 40 pts
- Steadiness (typical swing 5.0pp) → 21.4 of 25 pts
- Pace (median 12% YoY) → 0 of 20 pts
- Latest quarter (8.6% YoY) → 0 of 15 pts
- Score: 24 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 11.9% | 12% | 5.0pp | 3 of 40 | 1 |
| EPSEPS | 15.4% | 12.3% | 190.7pp | 15 of 39 | 8 |
| Op cash flowOperating cash flow | 12.7% | 10.6% | 112.0pp | 17 of 39 | 16 |
| EBITDAEBITDA | 15% | 13.4% | 14.9pp | 14 of 40 | 4 |
| FCFFree cash flow | 13.1% | 10.8% | 314.5pp | 18 of 39 | 16 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: RMD on the compounders surface · All compounders, ranked